T. Rowe Price Investment Management Inc. purchased a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 3,136,331 shares of the company's stock, valued at approximately $60,939,000. T. Rowe Price Investment Management Inc. owned about 1.31% of Cellebrite DI at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of the company. Assetmark Inc. purchased a new position in shares of Cellebrite DI during the first quarter valued at approximately $33,000. Catalyst Capital Advisors LLC acquired a new position in Cellebrite DI during the first quarter worth approximately $51,000. Gen Wealth Partners Inc acquired a new position in shares of Cellebrite DI in the 4th quarter valued at $85,000. NewEdge Advisors LLC increased its holdings in shares of Cellebrite DI by 600.7% during the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after buying an additional 3,352 shares during the last quarter. Finally, JT Stratford LLC purchased a new position in shares of Cellebrite DI in the 1st quarter worth $209,000. Institutional investors and hedge funds own 45.88% of the company's stock.
Cellebrite DI Stock Up 1.1%
CLBT traded up $0.18 during trading on Thursday, reaching $16.65. The stock had a trading volume of 785,588 shares, compared to its average volume of 1,667,127. The stock has a 50 day moving average of $14.96 and a two-hundred day moving average of $17.33. Cellebrite DI Ltd. has a 1-year low of $13.10 and a 1-year high of $26.30. The firm has a market capitalization of $3.99 billion, a price-to-earnings ratio of -21.88, a price-to-earnings-growth ratio of 2.87 and a beta of 1.27.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.01. The company had revenue of $113.28 million for the quarter, compared to the consensus estimate of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The company's revenue was up 18.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Cellebrite DI from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. Lake Street Capital lowered their price objective on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research note on Friday, August 15th. Needham & Company LLC cut their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, August 14th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat, Cellebrite DI presently has a consensus rating of "Buy" and a consensus price target of $22.40.
View Our Latest Stock Report on Cellebrite DI
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Read More
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
